Real-world evidence and patient preference for subcutaneous intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis – initial results from the observational SISTER study

Real-world evidence and patient preference for subcutaneous intravenous natalizumab in the treatment of relapsing-remitting multiple sclerosis – initial results from the observational SISTER study

Background: The consideration of patient preference for a certain drug route of administration (RoA) plays an important role in promoting patient adherence in chronic diseases. Natalizumab is an established treatment for relapsing-remitting multiple sclerosis (RRMS) and can be administered as intrav...

Full description

Bibliographic Details
Main Authors: Ralf Gold, Stephan Schmidt, Florian Deisenhammer, Jeremias Motte, Nils Richter, Kirsi Taipale, Hans Christian Salmen, Christian Bohland, Ksenija Schirduan
Format: Article
Language:English
Published: SAGE Publishing 2024-04-01
Series:Therapeutic Advances in Neurological Disorders
Online Access:https://doi.org/10.1177/17562864241241382

Internet

https://doi.org/10.1177/17562864241241382

Similar Items